Stocksigma LogoStocksigma Logo

Shukra Medtech Reports Robust Q2 FY27 Results Driven by Exports Expansion

Shukra Medtech reported a 652% YoY surge in standalone Q2 FY27 revenue to ₹44.20 crore, compared to ₹5.88 crore in Q2 FY26

Shukra Medtech Reports Robust Q2 FY27 Results Driven by Exports Expansion

Shukra Pharmaceuticals Ltd · Press Release · 05 Nov 2026, 8:05 pm

Shukra Medtech Reports Robust Q2 FY27 Results Driven by Exports Expansion Shukra Medtech reported a 652% YoY surge in standalone Q2 FY27 revenue to ₹44.20 crore, compared to ₹5.88 crore in Q2 FY26. EBITDA turned positive to ₹22.01 crore with a 49.8% margin, while PAT jumped 573% YoY to ₹16.01 crore. For H1 FY27, revenue expanded 501% YoY to ₹67.73 crore and PAT surged 811% YoY to ₹31.04 crore. Top-line growth was primarily driven by export expansion, alongside segment contributions of ₹32.27 crore from pharmaceuticals and ₹12.51 crore from MedTech.

Original exchange filing (PDF)

More announcements from Shukra Pharmaceuticals Ltd

All Shukra Pharmaceuticals Ltd announcements